TPMIC (Taiwan Precision Medicine Initiative on Cognitive Impairment) was established from the EMCIT study, the earlier study co-funded by Yen-Ling Chiu and Yi-Fang Chuang. The TPMIC study was granted by the Ministry of Science and Technology of Taiwan. It collects multi-domain information from healthy and MCI individuals of New Taipei City. This is the largest study conducted in Taiwan focusing on healthy elderly with a focus on precision medicine. During the baseline study conducted between 2021 and 2025, we collected almost one thousand individuals, conducted cognitive function tests, brain MRI imaging study (including resting-state functional imaging), gut microbiota metagenomics, blood-based biomarkers, amyloid-brain PET images, and genetic studies. The study is designed to be a longitudinal study, and participants are being actively monitored. The biological samples are stored in the FEMH biobank.

Based on the TPMIC study, many smaller research projects are being conducted by our collaborators in different academic institutions, including researchers in Korea and Sweden. We also held annual symposiums on related subjects since 2023.

TPMIC（Taiwan Precision Medicine Initiative on Cognitive Impairment，台灣認知障礙精準醫療計畫）源自 EMCIT 研究；EMCIT 是較早期由邱彥霖與莊宜芳共同開啟的研究。TPMIC 研究於2021年獲得台灣科技部健康大數據綱要計畫補助，主要收集新北市健康族群與輕度認知障礙（MCI）個案的多面向資料。本研究是台灣目前針對健康高齡者、並以精準醫療為核心所進行的最大規模研究。

在 2021 至 2025 年進行的基線研究期間，我們收案近一千名受試者，並完成認知功能測驗、腦部 MRI 影像檢查（包括靜息態功能性影像）、腸道菌相總體基因體分析、血液生物標記、腦部類澱粉蛋白 PET 影像，以及基因研究。本研究設計為縱貫性研究，目前仍持續積極追蹤受試者。

以 TPMIC 研究為基礎，我們的合作夥伴正在不同學術機構進行多項較小型的研究計畫，其中包括來自韓國與瑞典的研究人員。我們並且自2023年起每年舉辦國際研討會，進行相關主題的分享。